Gossamer Bio Faces Securities Class Action Over Failed Phase 3 Trial Disclosures
GOSS sits 47% above its 52-week low of $0.163.
Summary
Hagens Berman has filed a securities class action lawsuit against Gossamer Bio, alleging the company misled investors regarding the design and patient recruitment for its Phase 3 PROSERA trial. This legal action follows the February 23, 2026 announcement of the trial's failure, which caused an 80% stock decline. While the company's May 15, 2026 10-Q mentioned a class-action lawsuit, this news provides specific details on the firm and the allegations. This lawsuit further compounds the company's significant financial challenges, including a going concern warning, a Nasdaq delisting notice, and a recently initiated distressed debt exchange.
At the time of this announcement, GOSS was trading at $0.24 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $50.5M. The 52-week trading range was $0.16 to $3.87. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: PR Newswire.